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ABSTRACT 
 
Objective: To examine the performance of screening for early-, preterm- and 
term-preeclampsia (PE) at 11-13 weeks’ gestation by maternal factors and combinations 
of mean arterial pressure (MAP), uterine artery pulsatility index (UtA-PI), serum placental 
growth factor (PLGF) and serum pregnancy associated plasma protein-A (PAPP-A).   
 
Methods: The data for this study were derived from three previously reported prospective 
non-intervention screening studies at 11+0 – 13+6 weeks’ gestation in a combined total of 
61,174 singleton pregnancies, including 1,770 (2.9%) that developed PE. Bayes theorem 
was used to combine the prior distribution of the gestational age at delivery with PE, 
obtained from maternal characteristics, with various combinations of biomarker multiple 
of the median (MoM) values to derive the patient-specific risks of delivery with PE at <37 
weeks’ gestation. The performance of such screening was estimated. 
 
Results: In pregnancies that developed PE, compared to those without PE, the MoM 
values of UtA-PI and MAP were increased and PAPP-A and PLGF were decreased and 
the deviation from normal was greater for early than late PE for all four biomarkers. 
Combined screening by maternal factors, UtA-PI, MAP and PLGF predicted 90% of 
early-PE, 75% of preterm-PE and 41% of term-PE, at screen positive rate of 10%; 
inclusion of PAPP-A did not improve the performance of screening. The performance of 
screening depended on the racial origin of the women; in screening by a combination of 
maternal factors, MAP, UtA-PI and PLGF and use of the risk cut-off of 1 in 100 for PE at 
<37 weeks in Caucasian women, the screen positive rate was 10% and detection rates 
for early-, preterm- and term-PE were 88%, 69% and 40%, respectively. With the same 
method of screening and risk cut-off in women of Afro-Caribbean racial origin, the screen 
positive rate was 34% and detection rates for early-, preterm- and term-PE were 100%, 
92% and 75%, respectively. 
 
Conclusion: Screening by maternal factors and biomarkers at 11-13 weeks’ gestation can 
identify a high proportion of pregnancies that develop early- and preterm-PE.  
 
 
 
Key words: First trimester screening, Preeclampsia, Aspirin, ASPRE, SPREE, Pyramid 
of pregnancy care, Survival model, Bayes theorem, Uterine artery Doppler, Mean arterial 
pressure, Pregnancy associated plasma protein-A, Placental growth factor.  
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Introduction 
 
The ASPRE trial has shown that in pregnancies identified at 11-13 weeks’ gestation, by 
screening with maternal factors and biomarkers, as being at high-risk for preeclampsia 
(PE) administration of aspirin (150 mg/day from 11-14 weeks’ gestation to 36 weeks) 
reduces the rate of early-PE with delivery at <32 weeks’ gestation by about 90% and 
preterm-PE with delivery at <37 weeks by 60%; there was little evidence of a reduction in 
incidence of PE with delivery at term.1 Secondary analyses of the ASPRE trial 
demonstrated that first, the beneficial effect of aspirin depends on compliance and the 
reduction in incidence of preterm-PE may be about 75% in those with compliance of 
>90%,2 second, there is no heterogeneity in the aspirin effect in subgroups defined 
according to maternal characteristics, obstetrical history and history of pre-existing 
medical conditions, except for chronic hypertension, where aspirin may not be useful in 
the prevention of PE,3 and third, use of aspirin reduces the length of stay in neonatal 
intensive care unit by about 70%, mainly due to a decrease in the rate of births at <32 
weeks’ gestation because of prevention of early-PE.4 Recent meta-analyses reported that 
aspirin reduces the risk of preterm-PE by 67%, provided the daily dose of the drug 
is >100 mg and the gestational age at onset of therapy is <16 weeks,5 and that aspirin at a 
dose of ≥100 mg initiated at ≤16 weeks, rather than >16 weeks, may decrease the risk of 
placental abruption or antepartum hemorrhage.6  
 
The traditional approach to identify the group at high-risk for PE that would benefit from 
prophylactic use of aspirin is based on risk factors from maternal demographic 
characteristics and medical history, but such approach can identify only about 40% of 
preterm-PE, at false positive rate (FPR) of 10%.7-9 An alternative approach to screening 
for PE, which allows estimation of individual patient-specific risks of PE requiring delivery 
before a specified gestation, is to use Bayes theorem to combine the prior distribution of 
the gestational age at delivery with PE, obtained from maternal characteristics and 
medical history, with the results of various combinations of biophysical and biochemical 
measurements.8,10,11 Extensive research in the last decade has led to the identification of 
four potentially useful biomarkers at 11-13 weeks’ gestation: mean arterial pressure 
(MAP), uterine artery pulsatility index (UtA-PI), serum pregnancy associated plasma 
protein-A (PAPP-A) and serum placental growth factor (PLGF).9,12-14 We then carried out 
prospective screening for PE by the combined test at 11+0 -13+6 weeks’ gestation in three 
multicenter studies.9,12,15 The first study, which involved 35,948 pregnancies in two 
maternity hospitals in England, reported that the detection rate (DR) of preterm-PE was 
75% at FPR of 10%.12 The second study, which involved 8,775 pregnancies in 12 
maternity hospitals in England, Spain, Belgium, Italy and Greece, reported that the DR of 
preterm-PE was 75% at FPR of 10%.15 The third study, which involved 16,451 
pregnancies in seven maternity hospitals in England, reported that the DR of preterm-PE 
was 82% at screen positive rate (SPR) of 10%.12 
 
In this study we use the data from the three prospective screening studies to a combined 
total of 61,174 singleton pregnancies, including 1,770 (2.9%) that developed PE.9,12,15 
The objective is to examine in such large population the performance of screening for 
early-, preterm- and term-PE by maternal factors and different combinations of 
biomarkers in the total population and in subgroups of nulliparous and parous women of 
Caucasian and Afro-Caribbean racial origin and to recommend appropriate risk cut-offs 
for selecting the high-risk group that could benefit from prophylactic use of aspirin. 
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Methods 
 
Study population 
 
The data for this study were derived from three previously reported prospective 
non-intervention screening studies at 11+0 – 13+6 weeks’ gestation in a combined total of 
61,174 singleton pregnancies, including 1,770 (2.9%) that developed PE. Women with 
singleton pregnancies in the participating hospitals had a routine examination at 11+0 - 
13+6 weeks’ gestation. This visit included first, recording of maternal characteristics and 
medical history,8 second, measurement of the left and right UtA-PI by transabdominal 
color Doppler ultrasound and calculation of the mean PI,16 third, measurement of MAP by 
validated automated devices and standardized protocol,17 and fourth, measurement of 
serum concentration of PLGF and PAPP-A (DELFIA Xpress system, PerkinElmer Life and 
Analytical Sciences, Waltham, USA or BRAHMS KRYPTOR analyzer, Thermo Fisher 
Scientific, Hennigsdorf, Germany). Gestational age was determined from the fetal 
crown-rump length.18 The women gave written informed consent to participate in the 
studies, which were approved by the relevant research ethics committee in each 
participating country. 
 
The inclusion criteria were singleton pregnancy undergoing first-trimester combined 
screening for aneuploidy and subsequently delivering a phenotypically normal live birth or 
stillbirth at >24 weeks’ gestation. We excluded pregnancies with aneuploidies and major 
fetal abnormalities and those ending in termination, miscarriage or fetal death before 24 
weeks.  
 
Outcome measures were early-PE, preterm-PE and term-PE. Data on pregnancy 
outcome were collected from the hospital maternity records or the general medical 
practitioners of the women. The obstetric records of all women with pre-existing or 
pregnancy associated hypertension were examined to determine if the condition was PE, 
as defined by the International Society for the Study of Hypertension in Pregnancy.19  
 
Statistical analysis 
 
Patient-specific risks of delivery with PE at <37 weeks’ gestation were calculated using 
the competing risks model to combine the prior distribution of the gestational age at 
delivery with PE, obtained from maternal characteristics and medical history, with multiple 
of the median (MoM) values of MAP, UtA-PI, PLGF and PAPP-A.8 The performance of 
screening in the total population and in subgroups of nulliparous and parous women of 
Afro-Caribbean and Caucasian racial origin were estimated. The original MoM 
equations,20-23 have been updated and are reported in Appendix 1. The risk calculator is 
freely available at the website of the Fetal Medicine Foundation www.fetalmedicine.com.  
 
The statistical software package R was used for data analyses.24 The package pROC25 
was used for the receiver operating characteristic (ROC) curve analysis.   
 
 
Results 
 
Characteristics of the study population 
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The characteristics of the study population are summarized in Table 1. The incidence of 
early-, preterm- and term-PE was 0.2%, 0.8% and 2.1%, respectively. Women of 
Afro-Caribbean racial origin constituted 16.5% (10,108 of 61,174) of the population but 
they contributed 48.3%, 37.1% and 30.2% of the cases of early-, preterm- and term-PE, 
respectively. Women with chronic hypertension constituted 1.3% (798 of 61,174) of the 
population but they contributed 16.4%, 15.8% and 10.2% of the cases of early-, preterm- 
and term-PE, respectively. Parous women with no previous history of PE constituted 
49.5% (30,253 of 61,174) of the population and contributed 28.4%, 29.6% and 26.3% of 
the cases of early-, preterm- and term-PE, respectively. Parous women with previous 
history of PE constituted 3.0% (1,846 of 61,174) of the population and contributed 19.0%, 
15.4% and 11.8% of the cases of early-, preterm- and term-PE, respectively. 
 
Distribution of biomarkers  
 
The MoM values of the biomarkers in the PE group and the fitted regression relationships 
with gestational age at delivery are shown in Figure 1. All markers showed more 
separation at earlier than later gestations and this is reflected in their superior 
performance at detection of early than late PE. It is notable that the regression lines for 
UtA-PI and PAPP-A intersect 1 MoM close to term and therefore, these biomarkers 
perform poorly in screening for late PE. Conversely MAP shows a degree of separation 
from 1 MoM at term and the performance of MAP for term PE is relatively good.   
 
Performance of screening for preeclampsia 
 
The areas under the ROC (AUROC) curves and performance of screening for PE by 
maternal factors and biomarkers are given in Figure 2 and Tables 2-4. The best 
performance was achieved by a combination of maternal factors with MAP, UtA-PI and 
PLGF. Serum PAPP-A did not provide significant improvement to any combination of 
biomarkers which included serum PLGF.  
 
In screening for PE, at fixed SPR of 10%, the risk cut-off for a screen positive result and 
DR varied according to the combination of biomarkers used for screening (Table 2). For 
example, in screening by maternal factors the risk cut-off was 1 in 62 and the DR for 
early-PE, preterm-PE and term-PE were 53%, 45% and 34%, respectively, whereas, in 
screening by a combination of maternal factors, MAP, UtA-PI and PLGF the risk cut-off 
was 1 in 66 and the respective DRs were 90%, 75% and 41%. 
 
When the risk cut-off for PE at <37 weeks was fixed at 1 in 70 or 1 in 100 the SPR, DR 
and FPR varied with the combination of biomarkers used for screening (Table 3). For 
example, in screening by maternal factors at a risk cut-off of 1 in 70 the SPR was about 
12% and the DR’s for early-, preterm- and term-PE were 53%, 48% and 37%, 
respectively.  
 
The performance of screening at fixed risk cut-offs of 1 in 70 and 1 in 100 for women of 
Caucasian and Afro-Caribbean racial origin are shown in supplementary Tables 1 and 2. 
In Caucasian women screening by maternal factors, MAP, UtA-PI and PLGF and risk 
cut-off of 1 in 100, the SPR was 10% and the DR’s for early-, preterm- and term-PE were 
88%, 69% and 40%, respectively (Supplementary Table 1). In screening by the same 
method and risk cut-off in women of Afro-Caribbean racial origin the SPR was 34% and 
the DR’s for early-, preterm- and term-PE were 100%, 92% and 75%, respectively 
(Supplementary Table 2). The DR and SPR of screening for preterm-PE by a combination 
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of maternal factors, MAP, UtA-PI and PLGF at various risk cut-offs from 1 in 20 to 1 in 250 
in women of Caucasian and Afro-Caribbean racial origin are given in supplementary 
Table 3; the ROC curves were similar for the two racial groups, but at the same risk 
cut-off the DR and FPR were higher for women of Afro-Caribbean than Caucasian racial 
origin (supplementary Figure 1).  
 
Performance of screening for preeclampsia in subgroups 
 
The performance of screening by maternal factors, MAP, UtA-PI and PLGF for nulliparous 
and parous women of Caucasian and Afro-Caribbean racial origin are given in Table 4. At 
a risk cut-off for PE <37 weeks of 1 in 100, the DR and FPR were higher in nulliparous 
than in parous women, in parous women with a history of previous pregnancy with PE 
than in those without such history and in those of Afro-Caribbean rather than Caucasian 
racial origin. In all groups, the risk of being affected given a screen positive result was 
considerably higher that the prevalence of the disease, whereas in those with a screen 
negative result the risk was considerably reduced.  
 
The lowest risk group was found to be Caucasian parous women with no previous history 
of PE, which comprised 34.7% (21,225/61,174) of the population and accounted for 
12.8% (63/493) of cases of preterm-PE. In this group of women, the DR for preterm-PE 
was 54% and the SPR was 3.7%; in total 624 tests would need to be performed for each 
true positive identified. The highest risk group, Afro-Caribbean women with previous 
history of PE, comprised 0.8% (493/61,174) of the population and accounted for 7.3% 
(36/493) of cases of preterm-PE. In this highest risk group, the DR for preterm-PE was 
100% and the FPR was 72.8%; in total 14 tests would need to be performed for each true 
positive identified. 
 
Performance of screening by NICE and ACOG guidelines 
 
The traditional approach to screening for PE is to identify risk factors from maternal 
demographic characteristics and medical history.26,27 According to the National Institute 
for Health and Clinical Excellence (NICE), in the UK, women should be considered to be 
at high-risk of developing PE if they have any one high-risk factor (hypertensive disease 
in previous pregnancy, chronic hypertension, chronic renal disease, diabetes mellitus or 
autoimmune disease) or any two moderate-risk factors (nulliparity, age >40 years, body 
mass index (BMI) >35 kg/m2, family history of PE or inter-pregnancy interval >10 years).26 
In the USA, according to the American Congress of Obstetricians and Gynecologists 
(ACOG) women are at high-risk of developing PE if they fulfill any of the following factors: 
PE in previous pregnancy, chronic hypertension, chronic renal disease, diabetes mellitus, 
systemic lupus erythematosus or thrombophilia, nulliparity, age >40 years, BMI >30 kg/m2, 
family history of PE, or conception by in vitro fertilization.27 
 
In our study population of 61,174 pregnancies, the SPR according to NICE guidelines 
was 11.5% (n=7,032) and according to ACOG guidelines it was 66.1% (n=40,465). The 
NICE screen positive group contained 53 (45.7%, 95% CI 36.9-54.8) of cases of 
early-PE, 207 (42.0%, 95% 37.7-46.4) of preterm-PE and 404 (31.6%, 95% CI 29.1-34.2) 
of term-PE. The ACOG screen positive group contained 105 (90.5%, 95% CI 83.8-94.6) 
of cases of early-PE, 440 (89.2%, 95% CI 86.2-91.7) of preterm-PE and 1,151 (90.1%, 
95% CI 88.4-91.7) of term-PE. 
 
Women with chronic hypertension 
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In the study population 1.3% (n=798) of women had chronic hypertension (CH) and in this 
group 19 (3.2%), 78 (13.2%) and 130 (22.0%) developed early-, preterm- and term-PE, 
respectively. In the women with CH screening by maternal factors, MAP, UtA-PI and 
PLGF and risk cut-off of 1 in 100, the SPR was 82.5% and the DR’s for early-, preterm- 
and term-PE were 100%, 97.4% and 89.2%, respectively. 
 
 
Discussion 
 
Selection of biomarkers 
 
In pregnancies that develop PE the MoM values of UtA-PI and MAP at 11-13 weeks’ 
gestation are increased and the values of serum PAPP-A and PLGF are decreased. For 
all biomarkers the deviation from normal is greater for early rather than late PE and 
therefore the performance of screening is inversely related to the gestational age at which 
delivery becomes necessary for maternal and or fetal indications. The best individual 
biomarker for preterm-PE was PLGF, followed by UtA-PI and MAP and then PAPP-A and 
the best performance was achieved by a combination of maternal factors, MAP, UtA-PI 
and serum PLGF; there was no further improvement in screening by the addition of 
PAPP-A. 
 
This study provides details on the performance of first-trimester screening for PE by all 
combinations of biomarkers. However, there are various levels of complexity and 
implications in terms of general applicability and costs for the various components of the 
combined test; the choice of which biomarkers should be used in a particular setting will 
ultimately depend not only on the basis of performance, but also the feasibility of 
implementation and health economic considerations. Recording maternal characteristics 
and medical history, measurement of blood pressure and hospital attendance at 11-13 
weeks’ gestation for an ultrasound scan are an integral part of routine antenatal care in 
many countries. Measurement of UtA-PI can be carried out by the same sonographers 
and ultrasound machines as part of the 11-13 weeks scan which is routinely performed in 
many countries; however, the sonographers will require training to carry out this test and 
the measurement would add 2-3 minutes to the current 20-30 minutes used for the scan. 
Measurement of serum PAPP-A and quality assurance for such measurement are 
already in place in centres providing routine first-trimester combined screening for Down 
syndrome. Measurement of serum PLGF can be undertaken on the same sample and by 
the same machines as for PAPP-A, but at a marginally increased cost. Extensive 
research has established reference ranges for each biomarker, described the maternal 
characteristics that affect the measurements (see Appendix 1) and developed the 
infrastructure for auditing of results. The software for estimation of patient-specific risk for 
PE by any combination of biomarkers is freely accessible (www.fetalmedicine.org). 
 
Screening for term-PE 
 
The performance of screening at 11-13 weeks’ gestation for term-PE is poor and 
prophylactic use of aspirin does not reduce the incidence of term-PE.1 Screening for 
term-PE is best performed at 35+0 - 36+6 weeks’ gestation by a combination of maternal 
factors, MAP, PLGF and serum soluble fms-like tyrosine kinase-1 (sFLT), with DR of 70% 
at SPR of 10%.28 The rationale for such late third-trimester screening is identification of a 
high-risk group that would benefit from close monitoring to minimize adverse perinatal 
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events for those that develop PE by determining the appropriate time and place for 
delivery. 
 
Performance of screening for preterm-PE 
 
The objective of screening at 11-13 weeks’ gestation is the identification of a group at 
high-risk for early- and preterm-PE and the reduction of such risk, by 90% and 60%, 
respectively, through the prophylactic use of aspirin.1 In our heterogeneous population, 
screening for PE by a combination of maternal factors, MAP, UtA-PI and serum PLGF at 
11-13 weeks’ gestation predicted 90% of early-PE and 75% of preterm-PE, at fixed SPR 
of 10%. The performance of screening by our method is by far superior to that of the 
traditional methods recommended by NICE and ACOG; in screening according to NICE 
guidelines the SPR was 12%, the DR of early-PE was 46% and DR of preterm-PE was 
42% and the respective values in screening according to ACOG guidelines were 66%, 
89% and 90%.    
 
The study has highlighted that in screening for PE at a fixed risk cut-off, the DR, SPR and 
FPR are influenced by the characteristics of the study population, which define the prior 
risk, and they are higher in nulliparous than in parous women and in those of 
Afro-Caribbean than Caucasian racial origin. In all groups, after combined screening, the 
risk of being affected given a screen positive result was considerably increased and if the 
screen result was negative the risk was considerably reduced. 
 
Selection of risk cut-off to define the high-risk group 
 
Randomized trials on the use of aspirin have reported that the drug is not associated with 
increased risk of adverse events and in the case of abruption or antepartum hemorrhage 
the risk may actually be reduced.6 In this respect, it may be acceptable that in screening 
for PE the SPR could be about 15% or even higher so as to maximize the DR. This can 
be contrasted with traditional screening for Down syndrome where the aim was to 
minimize the SPR because such group would be subjected to the risk of miscarriage from 
an invasive test; with the advent of cell free DNA testing the SPR can be increased to 
maximize the DR.  
 
In a Caucasian population, for risk cut-off of 1 in 100 and 1 in 150 the respective SPR’s 
are about 10% and 16%, the DR’s for early-PE are 88% and 94% and DR’s for 
preterm-PE are 69% and 81%. It would therefore be reasonable in screening for PE in a 
setting with a predominantly Caucasian population to use a risk cut-off of 1 in 150 to 
define the high-risk group that would benefit from prophylactic use of aspirin. However, at 
such risk cut-off it should be anticipated that for women of Afro-Caribbean racial origin the 
SPR would be about 43% with DR of early- and preterm-PE of 100% and 96%, 
respectively. This is an inevitable consequence of the fact that the prevalence of 
preterm-PE is more than three times as high in women of Afro-Caribbean than Caucasian 
racial origin. This is analogous to screening for Down syndrome where the risk cut-off is 
fixed and both the SPR and DR increase with increasing maternal age. It would therefore 
be inappropriate in screening for preterm-PE in a given country to fix the SPR and define 
different risk cut-offs for women of different racial origins, because such practice would 
merely mask the increased risk for PE in certain racial groups.  
 
Selective vs. universal screening 
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In the early stages of the clinical implementation of the first-trimester combined test for 
trisomy 21, in some countries the test was offered to the whole population, but in others it 
was offered selectively to women that were aged ≥35 years, or selectively to women aged 
<35 years while those ≥35 years were offered amniocentesis. However, it is now 
accepted that the best approach to screening is to offer the test to the whole population 
and then select the high-risk group in need of further investigations on the basis of the 
patient-specific risk derived from the combination of maternal age with a series of 
biomarkers, rather than use of arbitrary cut-offs in maternal age. 
 
Similar discussions are likely to occur concerning the clinical implementation of the 
first-trimester combined test in screening for preterm-PE. The best approach is universal 
screening of the whole population. We have demonstrated that in women of 
Afro-Caribbean racial background and in those with a prior history of PE there is a high 
prior risk for preterm-PE. After combined screening in some of these women the risk is 
substantially increased, whereas in others the risk is substantially reduced to below the 
background risk of the whole population. Similarly, we have previously reported that in 
ACOG or NICE screen positive women that are screen positive by the FMF algorithm, the 
incidence of preterm-PE is substantially increased, whereas in the FMF screen negative 
group the incidence is reduced to within or below background levels.29 
 
An alternative strategy would be to carry out contingent screening; the whole population 
undergoes primary screening by a combination of maternal factors and MAP and on the 
basis of risk a subgroup is selected for measurements of UtA-PI and PlGF.30 The main 
advantage of such approach is saving in costs and resources required. One option would 
be to apply the NICE or ACOG criteria to the primary screen, but the great disadvantage 
of this is that most cases of preterm-PE would be missed because the performance of 
these criteria is very poor. Another strategy is to screen the whole population by the NICE 
or ACOG guidelines, consider the screen positive group as being at high-risk for PE and 
then offer the combined test to the screen negative group to identify another high-risk 
group; such an approach is also irrational because it increases the FPR and fails to 
define the patient specific risk and therefore appropriate pregnancy management in 
ACOG or NICE screen positive women.  
 
There is also an argument that in screening studies only nulliparous women should be 
included because in parous women the prevalence of PE is very low. However, as 
demonstrated in this study parous women constituted about 50% of the population and 
contributed 45% of cases of preterm-PE, 30% from parous women without a history of PE 
and 15% from parous women with PE in a previous pregnancy. 
 
Patients with chronic hypertension 
 
Chronic hypertension, found in 1-2% of pregnancies, is the strongest risk factor for PE 
compared to other factors in maternal demographic characteristics and medical 
history.8,31 A subgroup analysis of the ASPRE trial reported that there was no evidence of 
heterogeneity in the beneficial effect of aspirin in reducing the incidence of preterm-PE in 
subgroups defined according to maternal age, body mass index, racial origin, method of 
conception, smoking, family history of PE, obstetrical history, and history of pre-existing 
medical conditions, except for CH.3 Therefore, in CH prophylactic use of aspirin may not 
be useful in the prevention of preterm-PE. It is possible that aspirin reduces preterm-PE 
by improving placentation and that in CH preterm-PE can develop in the absence or less 
severe degree of impaired placentation.32 The value of first-trimester screening for PE in 
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pregnancies with CH is first, to determine the patient-specific risk and on the basis of 
such risk determine the intensity of subsequent monitoring during pregnancy and second, 
to investigate the potential value of therapeutic interventions other than aspirin, such as 
strict control of blood pressure or prophylactic use of pravastatin.   
 
Strengths and limitations 
 
The strengths of this first-trimester screening study for PE are first, examination of a large 
population of pregnant women attending for routine care in a gestational age range which 
is widely used for assessment of risk for chromosomal abnormalities, second, recording 
of data on maternal characteristics and medical history to identify known risk factors 
associated with PE, third, use of a specific methodology and appropriately trained doctors 
to measure UtA-PI and MAP, fourth, use of automated machines to provide accurate 
measurement within 40 minutes of sampling of maternal serum concentration of 
metabolites that have been shown to be altered in pregnancies associated with impaired 
placentation, fifth, expression of the values of the biomarkers as MoMs after adjustment 
for factors that affect the measurements, and sixth, use of Bayes theorem to combine the 
prior risk from maternal factors with biomarkers to estimate patient-specific risks and the 
performance of screening for PE delivering at different stages of pregnancy. 
 
The reported indices of performance of screening apply to the particular study population 
and comparison between studies requires the appropriate adjustments for the 
characteristics of the population under investigation. Similarly, in the application of 
screening in different countries it is likely that adjustments would be necessary for the 
calculation of MoM values for the biomarkers. 
 
Conclusions 
 
Screening for preterm-PE at 11-13 weeks’ gestation identifies a group of pregnancies that 
would benefit from prophylactic use of aspirin. The performance of screening by a 
combination of maternal factors, MAP, UtA-PI and PLGF is by far superior to the 
traditional methods of screening based on maternal factors alone. Screening for 
preterm-PE should be universal rather than selective and in countries with a 
predominantly Caucasian population it would be reasonable to use a risk cut-off of 1 in 
150 to define the high-risk group for treatment with aspirin. 
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Figure legends 
 
Figure 1. Scatter diagram and regression line for the relationship between UtA-PI, MAP, 
PAPP-A and PLGF MoM and gestational age at delivery in pregnancies with PE.  
 
Figure 2. Receiver operating characteristic curves for prediction of early-PE (left), 
preterm-PE (middle) and term-PE (right) by maternal factors (black) and combination of 
maternal factors with MAP (blue), MAP and UtA-PI (green), MAP and PLGF (purple) and 
MAP, UtA-PI and PLGF (red). 
 
Supplementary Figure 1. Receiver operating characteristic curves for prediction of 
preterm-PE by maternal factors, MAP, UtA-PI and PLGF in women of Caucasian (red) 
and Afro-Caribbean (black) racial origin. The areas under the curve are similar for the two 
racial groups (Caucasian: 0.903, 95% CI 0.886 to 0.921; Afro-Caribbean: 0.910, 95% CI 
0.889 to 0.931). However, at risk cut-off of 1 in 100 the DR and FPR are higher in women 
of Afro-Caribbean (black circle) than Caucasian (red circle) racial origin.    
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Table 1. Maternal and pregnancy characteristics of the study population. 
 
Maternal characteristics No PE 
(n=59,404) 
PE <32 w 
(n=116) 
PE <37 w 
(n=493) 
PE >37w 
(n=1,277) 
Age in years, median (IQR) 31.3 (27.1-35.0) 30.2 (25.8-35.1) 32.1 (27.5-36.0) 31.2 (26.9-35.2) 
Weight in Kg, median (IQR) 66.6 (59.0-77.0) 74.8 (65.0-89.6) 74.0 (63.4-86.7) 73.0 (63.0-87.0) 
Height in cm, median (IQR) 165 (160-169) 163 (159-167) 163 (158-168) 164 (160-168) 
Gestation at screening in weeks, median (IQR) 12.7 (12.3-13.1) 12.6 (12.2-13.1) 12.7 (12.3-13.1) 12.7 (12.3-13.1) 
Racial origin     
  Caucasian, n (%) 43,663 (73.5) 48 (41.4) 256 (51.9) 765 (59.9) 
  Afro-Caribbean, n (%) 9,539 (16.1) 56 (48.3) 183 (37.1) 386 (30.2) 
  South Asian, n (%) 3,332 (5.6) 9 (7.8) 38 (7.7) 76 (6.0) 
  East Asian, n (%) 1,383 (2.3) 0  4 (0.8) 20 (1.6) 
  Mixed, n (%) 1,487 (2.5) 3 (2.6) 12 (2.4) 30 (2.3) 
 Conception     
  Spontaneous, n (%) 57,315 (96.5) 112 (96.6) 459 (93.1) 1,218 (95.4) 
  Assisted, n (%) 2,089 (3.5) 4 (3.4) 34 (6.9) 59 (4.6) 
Cigarette smoking, n (%) 5,000 (8.4) 6 (5.2) 30 (6.1) 70 (5.5) 
Chronic hypertension, n (%) 590 (1.0) 19 (16.4) 78 (15.8) 130 (10.2) 
SLE / APS, n (%) 117 (0.2) 0 5 (1.0) 2 (0.2) 
Diabetes mellitus, n (%) 470 (0.8) 4 (3.4) 17 (3.4) 23 (1.8) 
Parity     
  Nulliparous, n (%) 28,014 (47.2) 61 (52.6) 271 (55.0) 790 (61.9) 
  Parous no previous PE, n (%) 29,771 (50.1) 33 (28.4) 146 (29.6) 336 (26.3) 
  Parous previous PE, n (%) 1,619 (2.7) 22 (19.0) 76 (15.4) 151 (11.8) 
Family history of PE, n (%) 2,256 (3.8) 10 (8.6) 56 (11.4) 90 (7.0) 
Pregnancy interval in years, median (IQR) 2.9 (1.8-4.8) 4.4 (2.3-7.4) 4.6 (2.6-7.6) 3.6 (2.2-6.3) 
Gestation at delivery in weeks, median (IQR) 40.0 (39.0-40.9) 29.4 (28.0-30.8) 34.4 (32.1-35.9) 39.1 (38.1-40.3) 
 
PE = preeclampsia; IQR = interquartile range; SLE = systemic erythematosus lupus; APS = 
antiphospholipid syndrome. 
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Table 2. Detection rate with 95% confidence interval, at screen positive rate of 10%, of 
preeclampsia with delivery at <32, <37 and >37 weeks’ gestation in screening by 
maternal factors, biomarkers and their combination. 
 
 
 
PE = preeclampsia; AUC = area under the curve; MAP = mean arterial pressure; UtA-PI = uterine 
artery pulsatility index; PAPP-A = pregnancy associated plasma protein-A; PLGF = placental 
growth factor. 
Method of screening 
Risk cut-off 
for PE <37 w 
PE <32 w PE <37 w PE ≥37 w 
AUC 
DR  
n/116 (%, 95% CI) 
AUC 
DR  
n/493 (%, 95% CI) 
AUC 
DR  
n/1,277 (95% CI) 
Maternal factors 1 in 62 0.809 61 (52.6; 43.6-61.4) 0.788 221 (44.8; 40.5-49.2) 0.735 428 (33.5; 31.0-36.2) 
Maternal factors plus        
MAP 1 in 61 0.868 71 (61.2; 52.1-69.6) 0.841 249 (50.5; 46.1-54.9) 0.776 488 (38.2; 35.6-40.9) 
UtA-PI 1 in 60 0.903 81 (69.8; 61.0-77.4) 0.853 288 (58.4; 54.0-62.7) 0.733 449 (35.2; 32.6-37.8) 
PAPP-A 1 in 61 0.835 64 (55.2; 46.1-63.9) 0.810 239 (48.5; 44.1-52.9) 0.734 450 (35.2; 32.7-37.9) 
PLGF 1 in 62 0.911 84 (72.4; 63.7-79.3) 0.868 299 (60.6; 56.3-64.9) 0.745 441 (34.5; 32.0-37.2) 
MAP, UtA-PI 1 in 61 0.934 96 (82.8; 74.9-88.6) 0.891 337 (68.4; 64.1-72.3) 0.772 529 (41.4; 38.8-44.2) 
MAP, PAPP-A 1 in 60 0.888 76 (65.5; 56.5-73.5) 0.855 275 (55.8; 51.4-60.1) 0.774 499 (39.1; 36.4-41.8) 
MAP, PLGF 1 in 65 0.931 92 (79.3; 71.1-85.7) 0.895 326 (66.1; 61.8-70.2) 0.777 502 (39.3; 36.7-42.0) 
UtA-PI, PAPP-A 1 in 60 0.906 81 (69.8; 61.0-77.4) 0.861 292 (59.2; 54.8-63.5) 0.735 464 (36.3; 33.7-39.0) 
UtA-PI, PLGF 1 in 62 0.942 94 (81.0; 73.0-87.1) 0.892 330 (66.9; 62.7-70.9) 0.744 471 (36.9; 34.3-39.6) 
PLGF, PAPP-A 1 in 62 0.913 86 (74.1; 65.5-81.2) 0.869 313 (63.5; 59.2-67.6) 0.745 456 (35.7; 33.1-38.4) 
MAP, UtA-PI, PAPP-A 1 in 61 0.938 96 (82.8; 74.9-88.6) 0.896 336 (68.2; 63.9-72.1) 0.773 518 (40.6; 37.9-43.3) 
MAP, PAPP-A, PLGF 1 in 65 0.932 94 (81.0; 73.0-87.1) 0.896 332 (67.3; 63.1-71.3) 0.777 502 (39.3; 36.7-42.0) 
MAP, UtA-PI, PLGF 1 in 66 0.956 104 (89.7; 82.8-94.0) 0.915 369 (74.8; 70.8-78.5) 0.776 523 (41.0; 38.3-43.7) 
UtA-PI, PAPP-A, PLGF 1 in 63 0.942 94 (81.0; 73.0-87.1) 0.892 336 (68.2; 63.9-72.1) 0.745 471 (36.9; 34.3-39.6) 
MAP, UtA-PI, PAPP-A, PLGF 1 in 66 0.956 104 (89.7; 82.8-94.0) 0.916 369 (74.8; 70.8-78.5) 0.777 528 (41.3; 38.7-44.1) 
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Table 3. Screen positive rate false positive rate and detection rate of PE at <32, <37 and >37 weeks’ gestation, in screening by maternal factors and biomarkers at 
risk cut-off of >1 in 70 and >1 in 100 for PE at <37 weeks.  
 
PE = preeclampsia; DR = detection rate; SPR = screen positive rate; FPR = false positive rate; MAP = mean arterial pressure; UtA-PI = uterine artery pulsatility index; PAPP-A = 
pregnancy associated plasma protein-A; PLGF = placental growth factor 
Method of screening 
SPR 
n/61,174 (%) 
PE <32 w PE <37 w PE ≥37 w 
DR  
n/116 (%, 95% CI) 
FPR 
n/61,058 (%) 
DR  
n/493 (%, 95% CI) 
FPR 
n/60,681 (%) 
DR  
n/1,277 (%, 95% CI) 
FPR 
n/59,897 (%) 
Risk for PE <37 w >1 in 70        
Maternal factors 7,206 (11.8) 62 (53.4, 44.4-62.3) 7,144 (11.7) 238 (48.3, 43.9-52.7) 6,968 (11.5) 470 (36.8, 34.2-39.5) 6,736 (11.2) 
Maternal factors plus         
MAP 7,342 (12.0) 78 (67.2, 58.3-75.1) 7,264 (11.9) 275 (55.8, 51.4-60.1) 7,067 (11.6) 547 (42.8, 40.2-45.6) 6,795 (11.3) 
UtA-PI 7,456 (12.2) 83 (71.6, 62.8-79.0) 7,373 (12.1) 312 (63.3, 58.9-67.4) 7,144 (11.8) 502 (39.3, 36.7-42.0) 6,954 (11.6) 
PAPP-A 7,312 (12.0) 71 (61.2, 52.1-69.6) 7,241 (11.9) 262 (53.1, 48.7-57.5) 7,050 (11.6) 493 (38.6, 36.0-41.3) 6,819 (11.4) 
PLGF 6,910 (11.3) 86 (74.1, 65.5-81.2) 6,824 (11.2) 321 (65.1, 60.8-69.2) 6,589 (10.9) 480 (37.6, 35.0-40.3) 6,430 (10.7) 
MAP, UtA-PI 7,140 (11.7) 98 (84.5, 76.8-90.0) 7,042 (11.5) 348 (70.6, 66.4-74.4) 6,792 (11.2) 570 (44.6, 41.9-47.4) 6,570 (11.0) 
MAP, PAPP-A 7,303 (11.9) 82 (70.7, 61.9-78.2) 7,221 (11.8) 289 (58.6, 54.2-62.9) 7,014 (11.6) 557 (43.6, 40.9-46.4) 6,746 (11.3) 
MAP, PLGF 6,604 (10.8) 95 (81.9, 73.9-87.8) 6,509 (10.7) 338 (68.6, 64.3-72.5) 6,266 (10.3) 520 (40.7, 38.1-43.4) 6,084 (10.2) 
UtA-PI, PAPP-A 7,390 (12.1) 85 (73.3, 64.6-80.5) 7,305 (12.0) 314 (63.7, 59.4-67.8) 7,076 (11.7) 503 (39.4, 36.7-42.1) 6,887 (11.5) 
UtA-PI, PLGF 6,837 (11.2) 95 (81.9, 73.9-87.8) 6,742 (11.0) 346 (70.2, 66.0-74.1) 6,491 (10.7) 499 (39.1, 36.4-41.8) 6,338 (10.6) 
PLGF, PAPP-A 6,955 (11.4) 88 (75.9, 67.3-82.7) 6,867 (11.2) 331 (67.1, 62.9-71.1) 6,624 (10.9) 482 (37.7, 35.1-40.4) 6,473 (10.8) 
MAP, UtA-PI, PAPP-A 7,065 (11.5) 98 (84.5, 76.8-90.0) 6,967 (11.4) 353 (71.6, 67.5-75.4) 6,712 (11.1) 569 (44.6, 41.9-47.3) 6,496 (10.8) 
MAP, PAPP-A, PLGF 6,599 (10.8) 94 (81.0, 73.0-87.1) 6,505 (10.7) 337 (68.4, 64.1-72.3) 6,262 (10.3) 524 (41.0, 38.4-43.8) 6,075 (10.1) 
MAP, UtA-PI, PLGF 6,458 (10.6) 104 (89.7, 82.8-94.0) 6,354 (10.4) 372 (75.5, 71.5-79.1) 6,086 (10.0) 540 (42.3, 39.6-45.0) 5,918 (9.9) 
UtA-PI, PAPP-A, PLGF 6,856 (11.2) 95 (81.9, 73.9-87.8) 6,761 (11.1) 345 (70.0, 65.8-73.9) 6,511 (10.7) 498 (39.0, 36.4-41.7) 6,358 (10.6) 
MAP, UtA-PI, PAPP-A, PLGF 6,473 (10.6) 106 (91.4, 84.9-95.3) 6,367 (10.4) 375 (76.1, 72.1-79.6) 6,098 (10.0) 541 (42.4, 39.7-45.1) 5,932 (9.9) 
Risk for PE <37 w >1 in 100        
Maternal factors 11,713 (19.1) 73 (62.9, 53.9-71.2) 11,640 (19.1) 293 (59.4, 55.0-63.7) 11,420 (18.8) 619 (48.5, 45.7-51.2) 11,094 (18.5) 
Maternal factors plus        
MAP 11,184 (18.3) 87 (75.0, 66.4-82.0) 11,097 (18.2) 329 (66.7, 62.5-70.8) 10,855 (17.9) 703 (55.1, 52.3-57.8) 10,481 (17.5) 
UtA-PI 11,355 (18.6) 93 (80.2, 72.0-86.4) 11,262 (18.4) 355 (72.0, 67.9-75.8) 11,000 (18.1) 651 (51.0, 48.2-53.7) 10,704 (17.9) 
PAPP-A 11,704 (19.1) 78 (67.2, 58.3-75.1) 11,626 (19.0) 310 (62.9, 58.5-67.0) 11,394 (18.8) 635 (49.7, 47.0-52.5) 11,069 (18.5) 
PLGF 9,973 (16.3) 93 (80.2, 72.0-86.4) 9,880 (16.2) 353 (71.6, 67.5-75.4) 9,620 (15.9) 594 (46.5, 43.8-49.3) 9,379 (15.7) 
MAP, UtA-PI 10,336 (16.9) 104 (89.7, 82.8-94.0) 10,232 (16.8) 383 (77.7, 73.8-81.1) 9,953 (16.4) 689 (54.0, 51.2-56.7) 9,647 (16.1) 
MAP, PAPP-A 10,837 (17.7) 93 (80.2, 72.0-86.4) 10,744 (17.6) 340 (69.0, 64.8-72.9) 10,497 (17.3) 676 (52.9, 50.2-55.7) 10,161 (17.0) 
MAP, PLGF 9,372 (15.3) 101 (87.1, 79.8-92.0) 9,271 (15.2) 384 (77.9, 74.0-81.3) 8,988 (14.8) 633 (49.6, 46.8-52.3) 8,739 (14.6) 
UtA-PI, PAPP-A 11,161 (18.2) 95 (81.9, 73.9-87.8) 11,066 (18.1) 360 (73.0, 68.9-76.8) 10,801 (17.8) 630 (49.3, 46.6-52.1) 10,531 (17.6) 
UtA-PI, PLGF 9,576 (15.7) 102 (87.9, 80.8-92.7) 9,474 (15.5) 378 (76.7, 72.7-80.2) 9,198 (15.2) 601 (47.1, 44.3-49.8) 8,975 (15.0) 
PLGF, PAPP-A 9,915 (16.2) 96 (82.8, 74.9-88.6) 9,819 (16.1) 362 (73.4, 69.4-77.1) 9,553 (15.7) 604 (47.3, 44.6-50.0) 9,311 (15.5) 
MAP, UtA-PI, PAPP-A 10,211 (16.7) 104 (89.7, 82.8-94.0) 10,107 (16.6) 393 (79.7, 75.9-83.0) 9,818 (16.2) 682 (53.4, 50.7-56.1) 9,529 (15.9) 
MAP, PAPP-A, PLGF 9,296 (15.2) 102 (87.9, 80.8-92.7) 9,194 (15.1) 382 (77.5, 73.6-81.0) 8,914 (14.7) 624 (48.9, 46.1-51.6) 8,672 (14.5) 
MAP, UtA-PI, PLGF 8,970 (14.7) 109 (94.0, 88.1-97.1) 8,861 (14.5) 394 (79.9, 76.2-83.2) 8,576 (14.1) 655 (51.3, 48.6-54.0) 8,315 (13.9) 
UtA-PI, PAPP-A, PLGF 9,599 (15.7) 103 (88.8, 81.8-93.3) 9,496 (15.6) 380 (77.1, 73.2-80.6) 9,219 (15.2) 604 (47.3, 44.6-50.0) 8,995 (15.0) 
MAP, UtA-PI, PAPP-A, PLGF 8,980 (14.7) 109 (94.0, 88.1-97.1) 8,871 (14.5) 398 (80.7, 77.0-84.0) 8,582 (14.1) 651 (51.0, 48.2-53.7) 8,329 (13.9) 
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Table 4. Performance of screening for preterm-PE by an algorithm combining maternal factors, MAP, UtA-PI and PLGF at a risk cut-off 
of 1 in 100. 
Error! Not a valid link. 
Group N 
Prevalence 
n/N (%) 
Screen +ve 
rate n/N (%) 
False +ve 
rate (%) 
Detection rate  
% (95% CI) 
Risk of being affected given result: 
Screen +ve (%)* Screen -ve (%)** 
All pregnancies 61,174 493 (0.81) 8,970 (14.7) 8,576 (14.1) 394 (79.9, 76.2-83.2) 394/8,970 (4.4) 99/52,204 (0.2) 
Nulliparous 29,075 271 (0.93) 5,579 (19.2) 3,177 (10.9) 214 (79.0, 73.7-83.4) 214/5,579 (3.8) 57/23,496 (0.2) 
No previous PE 30,253 146 (0.48) 2,337 (7.7) 2,230 (7.4) 107 (73.3, 65.6-79.8) 107/2,337 (4.6) 39/27,916 (0.1) 
Previous PE 1,846 76 (4.12) 1,054 (57.1) 981 (53.1) 73 (96.1, 89.0-98.7) 73/1,054 (6.9) 3/792 (0.4) 
Afro-Caribbean 10,108 183 (1.81) 3,433 (34.0) 3,264 (32.9) 169 (92.3, 87.6-95.4) 169/3,433 (4.9) 14/6,675 (0.2) 
Nulliparous 3,742 72 (1.92) 1,691 (45.2) 1,624 (43.4) 67 (93.1, 84.8-97.0) 67/1,691 (4.0) 5/2,051 (0.2) 
No previous PE 5,873 75 (1.28) 1,347 (22.9) 1,281 (21.8) 66 (88.0, 78.7-93.6) 66/1,347 (4.9) 9/4,526 (0.2) 
Previous PE 493 36 (7.30) 395 (80.1) 359 (72.8) 36 (100, 90.4-100) 36/395 (9.1) 0/98 (0.0) 
Caucasian 44,684 256 (0.57) 4,647 (10.4) 4,470 (10.1) 177 (69.1, 63.2-74.5) 177/4,647 (3.8) 79/40,037 (0.2) 
Nulliparous 22,256 164 (0.74) 3,293 (14.8) 3,177 (14.3) 116 (70.7, 63.4-77.2) 116/3,293 (3.5) 48/18,963 (0.3) 
No previous PE 21,225 63 (0.30) 782 (3.7) 748 (3.5) 34 (54.0, 41.8-65.7) 34/782 (4.3) 29/20,443 (0.1) 
Previous PE 1,203 29 (2.41) 572 (47.5) 545 (45.3) 27 (93.1, 78.0-98.1) 27/572 (4.7) 2/631 (0.3) 
 
*Same as positive predictive value; ** same as 1 – negative predictive value  
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Supplementary Table 1. Detection rate of PE at <32, <37 and >37 weeks’ gestation, screen positive and false positive rates, in screening by maternal factors and 
biomarkers at risk cut-off of >1 in 70 and >1 in 100 for PE at <37 weeks in women of Caucasian racial origin.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PE = preeclampsia; DR = detection rate; SPR = screen positive rate; FPR = false positive rate; MAP = mean arterial pressure; UtA-PI = uterine artery pulsatility index; PAPP-A = 
pregnancy associated plasma protein-A; PLGF = placental growth factor. 
Method of screening 
SPR 
n/44,684 (%) 
PE <32 w PE <37 w PE ≥37 w 
DR  
n/48 (95% CI) 
FPR 
n/44,636 (%) 
DR 
n/256 (95% CI) 
FPR 
n/44,428 (%) 
DR  
n/765 (95% CI) 
FPR 
n/43,919 (%) 
Risk for PE <37 w >1 in 70        
Maternal factors 2,457 (5.5) 11 (22.9, 13.3-36.5) 2,446 (5.5) 73 (28.5, 23.3-34.3) 2,384 (5.4) 149 (19.5, 16.8-22.4) 2,308 (5.3) 
Maternal factors plus        
MAP 3,200 (7.2) 25 (52.1, 38.3-65.5) 3,175 (7.1) 103 (40.2, 34.4-46.3) 3,097 (7.0) 236 (30.8, 27.7-34.2) 2,964 (6.7) 
UtA-PI 3,246 (7.3) 26 (54.2, 40.3-67.4) 3,220 (7.2) 119 (46.5, 40.5-52.6) 3,127 (7.0) 193 (25.2, 22.3-28.4) 3,053 (7.0) 
PAPP-A 3,083 (6.9) 18 (37.5, 25.2-51.6) 3,065 (6.9) 91 (35.5, 29.9-41.6) 2,992 (6.7) 189 (24.7, 21.8-27.9) 2,894 (6.6) 
PLGF 2,982 (6.7) 26 (54.2, 40.3-67.4) 2,956 (6.6) 124 (48.4, 42.4-54.5) 2,858 (6.4) 194 (25.4, 22.4-28.6) 2,788 (6.3) 
MAP, UtA-PI 3,397 (7.6) 35 (72.9, 59.0-83.4) 3,362 (7.5) 147 (57.4, 51.3-63.3) 3,250 (7.3) 256 (33.5, 30.2-36.9) 3,141 (7.2) 
MAP, PAPP-A 3,526 (7.9) 27 (56.3, 42.3-69.3) 3,499 (7.8) 117 (45.7, 39.7-51.8) 3,409 (7.7) 250 (32.7, 29.5-36.1) 3,276 (7.5) 
MAP, PLGF 3,058 (6.8) 33 (68.8, 54.7-80.1) 3,025 (6.8) 140 (54.7, 48.6-60.7) 2,918 (6.6) 222 (29.0, 25.9-32.3) 2,836 (6.5) 
UtA-PI, PAPP-A 3,441 (7.7) 26 (54.2, 40.3-67.4) 3,415 (7.7) 124 (48.4, 42.4-54.5) 3,317 (7.5) 204 (26.7, 23.7-29.9) 3,237 (7.4) 
UtA-PI, PLGF 3,165 (7.1) 33 (68.8, 54.7-80.1) 3,132 (7.0) 140 (54.7, 48.6-60.7) 3,025 (6.8) 212 (27.7, 24.7-31.0) 2953 (6.7) 
PLGF, PAPP-A 3,045 (6.8) 28 (58.3, 44.3-71.2) 3,017 (6.8) 133 (52.0, 45.9-58.0) 2,912 (6.6) 193 (25.2, 22.3-28.4) 2852 (6.5) 
MAP, UtA-PI, PAPP-A 3,522 (7.9) 35 (72.9, 59.0-83.4) 3,487 (7.8) 154 (60.2, 54.1-66.0) 3,368 (7.6) 262 (34.2, 31.0-37.7) 3260 (7.4) 
MAP, PAPP-A, PLGF 3,086 (6.9) 32 (66.7, 52.5-78.3) 3,054 (6.8) 139 (54.3, 48.2-60.3) 2,947 (6.6) 230 (30.1, 26.9-33.4) 2856 (6.5) 
MAP, UtA-PI, PLGF 3,110 (7.0) 39 (81.3, 68.1-89.8) 3,071 (6.9) 165 (64.5, 58.4-70.1) 2,945 (6.6) 234 (30.6, 27.4-33.9) 2876 (6.5) 
UtA-PI, PAPP-A, PLGF 3,199 (7.2) 33 (68.8, 54.7-80.1) 3,166 (7.1) 142 (55.5, 49.3-61.4) 3,057 (6.9) 209 (27.3, 24.3-30.6) 2990 (6.8) 
MAP, UtA-PI, PAPP-A, PLGF 3,154 (7.1) 40 (83.3, 70.4-91.3) 3,114 (7.0) 169 (66.0, 60.0-71.5) 2,985 (6.7) 237 (31.0, 27.8-34.4) 2917 (6.6) 
Risk for PE <37 w >1 in 100        
Maternal factors 4,693 (10.5) 19 (39.6, 27.0-53.7) 4,674 (10.5) 100 (39.1, 33.3-45.2) 4,593 (10.3) 240 (31.4, 28.2-34.8) 4,453 (10.1) 
Maternal factors plus        
MAP 5,410 (12.1) 29 (60.4, 46.3-73.0) 5,381 (12.1) 136 (53.1, 47.0-59.2) 5,274 (11.9) 328 (42.9, 39.4-46.4) 5,082 (11.6) 
UtA-PI 5,481 (12.3) 32 (66.7, 52.5-78.3) 5,449 (12.2) 146 (57.0, 50.9-63.0) 5,335 (12.0) 281 (36.7, 33.4-40.2) 5,200 (11.8) 
PAPP-A 5,489 (12.3) 22 (45.8, 32.6-59.7) 5,467 (12.2) 119 (46.5, 40.5-52.6) 5,370 (12.1) 272 (35.6, 32.2-39.0) 5,217 (11.9) 
PLGF 4,761 (10.7) 31 (64.6, 50.4-76.6) 4,730 (10.6) 149 (58.2, 52.1-64.1) 4,612 (10.4) 255 (33.3, 30.1-36.8) 4,506 (10.3) 
MAP, UtA-PI 5,360 (12.0) 40 (83.3, 70.4-91.3) 5,320 (11.9) 174 (68.0, 62.0-73.4) 5,186 (11.7) 326 (42.6, 39.2-46.2) 5,034 (11.5) 
MAP, PAPP-A 5,585 (12.5) 33 (68.8, 54.7-80.1) 5,552 (12.4) 150 (58.6, 52.5-64.5) 5,435 (12.2) 324 (42.4, 38.9-45.9) 5,261 (12.0) 
MAP, PLGF 4,683 (10.5) 37 (77.1, 63.5-86.7) 4,646 (10.4) 172 (67.2, 61.2-72.7) 4,511 (10.2) 290 (37.9, 34.5-41.4) 4,393 (10.0) 
UtA-PI, PAPP-A 5,672 (12.7) 35 (72.9, 59.0-83.4) 5,637 (12.6) 156 (60.9, 54.8-66.7) 5,516 (12.4) 278 (36.3, 33.0-39.8) 5,394 (12.3) 
UtA-PI, PLGF 4,765 (10.7) 38 (79.2, 65.7-88.3) 4,727 (10.6) 164 (64.1, 58.0-69.7) 4,601 (10.4) 260 (34.0, 30.7-37.4) 4,505 (10.3) 
PLGF, PAPP-A 4,819 (10.8) 33 (68.8, 54.7-80.1) 4,786 (10.7) 155 (60.5, 54.5-66.3) 4,664 (10.5) 261 (34.1, 30.8-37.6) 4,558 (10.4) 
MAP, UtA-PI, PAPP-A 5,431 (12.2) 41 (85.4, 72.8-92.8) 5,390 (12.1) 181 (70.7, 64.9-75.9) 5,250 (11.8) 327 (42.7, 39.3-46.3) 5,104 (11.6) 
MAP, PAPP-A, PLGF 4,714 (10.5) 38 (79.2, 65.7-88.3) 4,676 (10.5) 172 (67.2, 61.2-72.7) 4,542 (10.2) 283 (37.0, 33.7-40.5) 4,431 (10.1) 
MAP, UtA-PI, PLGF 4,647 (10.4) 42 (87.5, 75.3-94.1) 4,605 (10.3) 177 (69.1, 63.2-74.5) 4,470 (10.1) 307 (40.1, 36.7-43.7) 4,340 (9.9) 
UtA-PI, PAPP-A, PLGF 4,818 (10.8) 40 (83.3, 70.4-91.3) 4,778 (10.7) 166 (64.8, 58.8-70.4) 4,652 (10.5) 267 (34.9, 31.6-38.4) 4,551 (10.4) 
MAP, UtA-PI, PAPP-A, PLGF 4,678 (10.5) 42 (87.5, 75.3-94.1) 4,636 (10.4) 181 (70.7, 64.9-75.9) 4,497 (10.1) 304 (39.7, 36.3-43.3) 4,374 (10.0) 
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Supplementary Table 2. Detection rate of PE at <32, <37 and >37 weeks’ gestation, screen positive and false positive rates, in screening by maternal factors and biomarkers at risk 
cut-off of >1 in 70 and >1 in 100 for PE at <37 weeks in women of Afro-Caribbean 
racial origin.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PE = preeclampsia; DR = detection rate; SPR = screen positive rate; FPR = false positive rate; MAP = mean arterial pressure; UtA-PI = uterine artery pulsatility index; PAPP-A = 
pregnancy associated plasma protein-A; PLGF = placental growth factor. 
Method of screening 
SPR 
n/10,108 (%) 
PE <32 w PE <37 w PE ≥37 w 
DR 
n/56 (95% CI) 
FPR 
n/10,052 (%) 
DR  
n/183 (95% CI) 
FPR 
n/9,925 (%) 
DR  
n/386 (95% CI) 
FPR 
n/9,722 (%) 
        
Risk for PE <37 w >1 in 70        
Maternal factors 4,185 (41.4) 47 (83.9, 72.2-91.3) 4,138 (41.2) 141 (77.0, 70.4-82.6) 4,044 (40.7) 286 (74.1, 69.5-78.2) 3,899 (40.1) 
Maternal factors plus        
MAP 3,459 (34.2) 46 (82.1, 70.2-90.0) 3,413 (34.0) 142 (77.6, 71.0-83.0) 3,317 (33.4) 268 (69.4, 64.7-73.8) 3,191 (32.8) 
UtA-PI 3,505 (34.7) 50 (89.3, 78.5-95.0) 3,455 (34.4) 155 (84.7, 78.8-89.2) 3,350 (33.8) 268 (69.4, 64.7-73.8) 3,237 (33.3) 
PAPP-A 3,548 (35.1) 48 (85.7, 74.3-92.6) 3,500 (34.8) 144 (78.7, 72.2-84.0) 3,404 (34.3) 264 (68.4, 63.6-72.8) 3,284 (33.8) 
PLGF 3,245 (32.1) 54 (96.4, 87.9-99.0) 3,191 (31.7) 161 (88.0, 82.5-91.9) 3,084 (31.1) 252 (65.3, 60.4-69.9) 2,993 (30.8) 
MAP, UtA-PI 3,045 (30.1) 53 (94.6, 85.4-98.2) 2,992 (29.8) 157 (85.8, 80.0-90.1) 2,888 (29.1) 266 (68.9, 64.1-73.3) 2,779 (28.6) 
MAP, PAPP-A 3,093 (30.6) 49 (87.5, 76.4-93.8) 3,044 (30.3) 138 (75.4, 68.7-81.1) 2,955 (29.8) 259 (67.1, 62.3-71.6) 2,834 (29.2) 
MAP, PLGF 2,883 (28.5) 54 (96.4, 87.9-99.0) 2,829 (28.1) 159 (86.9, 81.2-91.0) 2,724 (27.4) 252 (65.3, 60.4-69.9) 2,631 (27.1) 
UtA-PI, PAPP-A 3,239 (32.0) 52 (92.9, 83.0-97.2) 3,187 (31.7) 153 (83.6, 77.6-88.3) 3,086 (31.1) 259 (67.1, 62.3-71.6) 2,980 (30.7) 
UtA-PI, PLGF 2,992 (29.6) 53 (94.6, 85.4-98.2) 2,939 (29.2) 162 (88.5, 83.1-92.4) 2,830 (28.5) 247 (64.0, 59.1-68.6) 2,745 (28.2) 
PLGF, PAPP-A 3,208 (31.7) 54 (96.4, 87.9-99.0) 3,154 (31.4) 160 (87.4, 81.9-91.5) 3,048 (30.7) 253 (65.5, 60.7-70.1) 2,955 (30.4) 
MAP, UtA-PI, PAPP-A 2,870 (28.4) 53 (94.6, 85.4-98.2) 2,817 (28.0) 156 (85.2, 79.4-89.7) 2,714 (27.3) 260 (67.4, 62.5-71.8) 2,610 (26.8) 
MAP, PAPP-A, PLGF 2,854 (28.2) 54 (96.4, 87.9-99.0) 2,800 (27.9) 159 (86.9, 81.2-91.0) 2,695 (27.2) 249 (64.5, 59.6-69.1) 2,605 (26.8) 
MAP, UtA-PI, PLGF 2,693 (26.6) 55 (98.2, 90.6-99.7) 2,638 (26.2) 161 (88.0, 82.5-91.9) 2,532 (25.5) 261 (67.6, 62.8-72.1) 2,432 (25.0) 
UtA-PI, PAPP-A, PLGF 2,969 (29.4) 53 (94.6, 85.4-98.2) 2,916 (29.0) 161 (88.0, 82.5-91.9) 2,808 (28.3) 249 (64.5, 59.6-69.1) 2,720 (28.0) 
MAP, UtA-PI, PAPP-A, PLGF 2,664 (26.4) 56 (100, 93.6-100) 2,608 (25.9) 161 (88.0, 82.5-91.9) 2,503 (25.2) 259 (67.1, 62.3-71.6) 2,405 (24.7) 
Risk for PE <37 w >1 in 100        
Maternal factors 5,865 (58.0) 49 (87.5, 76.4-93.8) 5,816 (57.9) 160 (87.4, 81.9-91.5) 5,705 (57.5) 323 (83.7, 79.7-87.0) 5,542 (57.0) 
Maternal factors plus        
MAP 4,665 (46.2) 50 (89.3, 78.5-95.0) 4,615 (45.9) 155 (84.7, 78.8-89.2) 4,510 (45.4) 306 (79.3, 75.0-83.0) 4,359 (44.8) 
UtA-PI 4,697 (46.5) 52 (92.9, 83.0-97.2) 4,645 (46.2) 163 (89.1, 83.7-92.8) 4,534 (45.7) 311 (80.6, 76.3-84.2) 4,386 (45.1) 
PAPP-A 5,023 (49.7) 49 (87.5, 76.4-93.8) 4,974 (49.5) 153 (83.6, 77.6-88.3) 4,870 (49.1) 309 (80.1, 75.8-83.7) 4,714 (48.5) 
PLGF 4,183 (41.4) 54 (96.4, 87.9-99.0) 4,129 (41.1) 163 (89.1, 83.7-92.8) 4,020 (40.5) 290 (75.1, 70.6-79.2) 3,893 (40.0) 
MAP, UtA-PI 3,954 (39.1) 53 (94.6, 85.4-98.2) 3,901 (38.8) 163 (89.1, 83.7-92.8) 3,791 (38.2) 302 (78.2, 73.9-82.1) 3,652 (37.6) 
MAP, PAPP-A 4,201 (41.6) 51 (91.1, 80.7-96.1) 4,150 (41.3) 151 (82.5, 76.4-87.3) 4,050 (40.8) 291 (75.4, 70.9-79.4) 3,910 (40.2) 
MAP, PLGF 3,743 (37.0) 54 (96.4, 87.9-99.0) 3,689 (36.7) 167 (91.3, 86.3-94.6) 3,576 (36.0) 290 (75.1, 70.6-79.2) 3,453 (35.5) 
UtA-PI, PAPP-A 4,349 (43.0) 52 (92.9, 83.0-97.2) 4,297 (42.7) 161 (88.0, 82.5-91.9) 4,188 (42.2) 293 (75.9, 71.4-79.9) 4,056 (41.7) 
UtA-PI, PLGF 3,839 (38.0) 54 (96.4, 87.9-99.0) 3,785 (37.7) 168 (91.8, 86.9-95.0) 3,671 (37.0) 289 (74.9, 70.3-78.9) 3,550 (36.5) 
PLGF, PAPP-A 4,091 (40.5) 55 (98.2, 90.6-99.7) 4,036 (40.2) 165 (90.2, 85.0-93.7) 3,926 (39.6) 292 (75.6, 71.1-79.7) 3,799 (39.1) 
MAP, UtA-PI, PAPP-A 3,777 (37.4) 53 (94.6, 85.4-98.2) 3,724 (37.0) 165 (90.2, 85.0-93.7) 3,612 (36.4) 293 (75.9, 71.4-79.9) 3,484 (35.8) 
MAP, PAPP-A, PLGF 3,661 (36.2) 55 (98.2, 90.6-99.7) 3,606 (35.9) 166 (90.7, 85.6-94.1) 3,495 (35.2) 288 (74.6, 70.0-78.7) 3,373 (34.7) 
MAP, UtA-PI, PLGF 3,433 (34.0) 56 (100, 93.6-100) 3,377 (33.6) 169 (92.3, 87.6-95.4) 3,264 (32.9) 288 (74.6, 70.0-78.7) 3,145 (32.3) 
UtA-PI, PAPP-A, PLGF 3,814 (37.7) 54 (96.4, 87.9-99.0) 3,760 (37.4) 168 (91.8, 86.9-95.0) 3,646 (36.7) 289 (74.9, 70.3-78.9) 3,525 (36.3) 
MAP, UtA-PI, PAPP-A, PLGF 3,410 (33.7) 56 (100, 93.6-100) 3,354 (33.4) 169 (92.3, 87.6-95.4) 3,241 (32.7) 287 (74.4, 69.8-78.5) 3,123 (32.1) 
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Supplementary Table 3. Performance of screening for early- and preterm-PE by an 
algorithm combining maternal factors, MAP, UtA-PI and PLGF at different risk cut-offs in 
in women of Caucasian and Afro-Caribbean racial origin. 
 
 
SPR = screen positive rate; DR = detection rate. 
 
 
Risk 
cut-off 
Caucasian racial origin Afro-Caribbean racial origin 
SPR 
n / 44,684 (%) 
DR PE <32 w 
n / 48 (%) 
DR PE<37 w 
n / 256 (%, 95% CI) 
SPR 
n / 10,108 (%) 
DR PE <32 w 
n / 56 (%) 
DR PE <37 w 
n / 183 (%, 95% CI) 
1 in 20 674 (1.5) 20 (41.7, 28.9-55.7) 80 (31.3, 25.9-37.2) 1,011 (10.0) 50 (89.3, 78.5-95.0) 134 (73.2, 66.4-79.1) 
1 in 50 2,129 (4.8) 35 (72.9, 59.0-83.4) 143 (55.9, 49.7-61.8) 2,126 (21.0) 53 (94.6, 85.4-98.2) 155 (84.7, 78.8-89.2) 
1 in 70 3,110 (7.0) 39 (81.3, 68.1-89.8) 165 (64.5, 58.4-70.1) 2,693 (26.6) 55 (98.2, 90.6-99.7) 161 (88.0, 82.5-91.9) 
1 in 100 4,647 (10.4) 42 (87.5, 75.3-94.1) 177 (69.1, 63.2-74.5) 3,433 (34.0) 56 (100, 93.6-100) 169 (92.3, 87.6-95.4) 
1 in 150 6,960 (15.6) 45 (93.8, 83.2-97.9) 206 (80.5, 75.2-84.9) 4,383 (43.4) 56 (100, 93.6-100) 175 (95.6, 91.6-97.8) 
1 in 200 9,016 (20.2) 45 (93.8, 83.2-97.9) 213 (83.2, 78.1-87.3) 5,098 (50.4) 56 (100, 93.6-100) 180 (98.4, 95.3-99.4) 
1 in 250 10,858 (24.3) 45 (93.8, 83.2-97.9) 218 (85.2, 80.3-89.0) 5610 (55.5) 56 (100, 93.6-100) 180 (98.4, 95.3-99.4) 
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Appendix 1: formulas for calculation of multiple of the median (MoM) values at 11- 
 
13 weeks’ gestation. 
 
These are default parameters and their suitability should be checked before use.   
 
Mean arterial pressure 
 
The model was derived from the study of 69,808 singleton pregnancies at 11-13 weeks’ 
gestation. 
 
 
Term Estimate 
Intercept 1.936400000 
Gestational age in days - 77 0.000428017 
(Gestational age in days – 77)^2 -0.000028811 
Weight in kg - 69 0.001205300 
(Weight in kg - 69)^2 -0.000009280 
Height in cm - 164 -0.000181570 
Racial origin: Afro-Caribbean -0.003930000 
Smoker -0.008640000 
Medical history of chronic hypertension 0.053630000 
Medical history of chronic hypertension x (weight in kg - 69) -0.000239750 
Medical history of diabetes mellitus Type 1 0.004370000 
Medical history of diabetes mellitus Type 2 treated with insulin 0.004370000 
Medical history of diabetes mellitus Type 2 not treated with insulin 0.004370000 
Family history of preeclampsia 0.006240000 
Parous with no history of preeclampsia -0.006630000 
Parous with no history of preeclampsia x (pregnancy interval in years - 2) 0.000826390 
Parous with history of preeclampsia 0.008570000 
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Uterine artery pulsatility index 
 
The model was derived from the study of 83,640 singleton pregnancies at 11-13 weeks’ 
gestation. 
 
Term Estimate 
Intercept 0.264570000 
Gestational age in days - 77 -0.004838365 
Weight in kg - 69 -0.000874430 
(Weight in kg - 69)^2 0.000007330 
Maternal age in years - 35 -0.000641750 
Racial origin: Afro-Caribbean 0.021620000 
Racial origin: East Asian 0.007630000 
Racial origin: Mixed 0.011990000 
Medical history of diabetes mellitus Type 1 -0.027490000 
Parous with no history of preeclampsia -0.002950000 
Parous with history of preeclampsia 0.009650000 
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Serum placental growth factor 
 
The model was derived from the study of 42,355 singleton pregnancies at 11-13 weeks’ 
gestation, including 7,065 measured by the Cobas e411 system (Roche Diagnostics), 
2,143 measured by BRAHMS KRYPTOR compact PLUS (Thermo Fisher Scientific), and 
33,147 measured by DELFIA Xpress system (PerkinElmer Life and Analytical Sciences). 
 
Term Estimate 
Intercept: DELFIA Xpress 1.332959332 
Intercept: Cobas e411  1.542535524 
Intercept: BRAHMS KRYPTOR 1.430615169 
Gestational age in days - 77 0.012263018 
(Gestational age in days – 77)^2 0.000149743 
Weight in kg - 69 -0.001682761 
(Weight in kg - 69)^2 0.000008780 
Maternal age in years - 35 0.002174191 
Racial origin: Afro-Caribbean 0.193561059 
Racial origin: South Asian 0.072679108 
Racial origin: East Asian 0.034550109 
Racial origin: Mixed 0.079010576 
Smoker 0.160836176 
Medical history of diabetes mellitus Type 1 -0.029630891 
Medical history of diabetes mellitus Type 2 treated with insulin -0.039984195 
In vitro fertilization -0.022250585 
Parous with no history of preeclampsia 0.020750050 
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Serum pregnancy-associated plasma protein-A (PAPP-A) 
 
The model was derived from the previously published parameters33 from data on over 
200,000 measurements at 8-14 weeks’ with additional data on singleton pregnancies at 
11-13 weeks’ gestation, including 6,906 measured by the Cobas e411 system (Roche 
Diagnostics), and 97,405 measured by DELFIA Xpress system (PerkinElmer Life and 
Analytical Sciences). 
 
Term Estimate 
Intercept: DELFIA Xpress 0.075861 
Intercept: Cobas e411  0.22122 
Intercept: BRAHMS KRYPTOR 0.19496 
Gestational age in days - 77 0.0284402 
(Gestational age in days – 77)^2 -0.000232421 
(Gestational age in days – 77)^3 0.000012437 
Weight in kg - 69 -0.0073078 
(Weight in kg - 69)^2 2.92E-05 
Racial origin: Afro-Caribbean 0.1633 
Racial origin: Afro-Caribbean*( Gestational age in days - 77) 0.003206 
Racial origin: South Asian 0.01986849 
Racial origin: East Asian 0.0187 
Smoker -0.07827 
Smoker*(Gestational age in days - 77) -0.001495 
Medical history of diabetes mellitus Type 1 -0.00958 
Medical history of diabetes mellitus Type 2 treated with insulin -0.09492 
Medical history of diabetes mellitus Type 2 not treated with insulin -0.05282 
In vitro fertilization -0.0943 
In vitro fertilization*(Gestational age in days - 77) 0.002755 
Parous with history of preeclampsia -0.05658 
Parous with no history of preeclampsia -0.02402 
 
